Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-02-15
DOI
10.1002/cpt.1046
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metabolite profiling in early clinical drug development: current status and future prospects
- (2017) Mike Ufer et al. Expert Opinion on Drug Metabolism & Toxicology
- The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
- (2017) Alexander Treiber et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers
- (2015) Annemiek Vermeeren et al. SLEEP
- On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers
- (2015) Annemiek Vermeeren et al. SLEEP
- Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators
- (2014) Anthony L Gotter et al. BMC NEUROSCIENCE
- Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
- (2014) L. Citrome INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Motivational activation: a unifying hypothesis of orexin/hypocretin function
- (2014) Stephen V Mahler et al. NATURE NEUROSCIENCE
- Opportunities and perspectives for developing orexin receptor antagonists
- (2014) Michel A. Steiner et al. Frontiers in Neuroscience
- How the accelerator MS community are trying to fit into the regulatory framework: are the Bioanalytical Method Validation guidances relevant?
- (2013) Mark A Seymour Bioanalysis
- Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial
- (2012) P Hoever et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Microdosing: A Critical Assessment of Human Data
- (2012) Malcolm Rowland JOURNAL OF PHARMACEUTICAL SCIENCES
- Orexin receptor antagonism: an ascending multiple-dose study with almorexant
- (2012) Petra Hoever et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist
- (2011) Christopher J. Winrow et al. JOURNAL OF NEUROGENETICS
- Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant
- (2010) P Hoever et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Addressing metabolite safety during first-in-man studies using14C-labeled drug and accelerator mass spectrometry
- (2010) Graham Lappin et al. Bioanalysis
- Orexin/Hypocretin: A Neuropeptide at the Interface of Sleep, Energy Homeostasis, and Reward System
- (2009) N. Tsujino et al. PHARMACOLOGICAL REVIEWS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now